OR7A15P

Across TCGA pan-cancer cohorts, OR7A15P RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated OR7A15P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR7A15P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated OR7A15P expression acts as an unfavorable survival marker.

LIHC, LUAD, and CESC are the cancer types where OR7A15P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.122	0.723	<.001	135	view →
LUAD	OS	Tertile	II,III,IV	0.349	0.686	.006	48	view →
CESC	OS	Tertile	III,IV	0.068	0.756	<.001	36	view →
THYM	DFS	Tertile	II,III,IV	0.530	0.884	<.001	36	view →
SKCM	DFS	Tertile	III,IV	0.198	0.611	<.001	33	view →
SARC	DFS	Tertile	All	0.163	0.646	<.001	33	view →
THCA	DFS	Tertile	II,III,IV	0.082	0.762	<.001	18	view →
COAD	DFS	Tertile	II,III,IV	0.374	0.653	.027	18	view →
LAML	DFS	Tertile	All	0.322	0.600	.041	18	view →
KIRC	OS	Tertile	All	0.523	0.653	.039	12	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →
PRAD	DFS	Tertile	All	0.873	0.936	.043	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

OR7A15P–LIHC (OS)

Open the LIHC breakdown →